SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coca-Cola Company (The). The Group's principal activities are manufacturing, distributing and marketing nonalcoholic beverage concentrates and syrups. The products of the Group include carbonated soft drinks and also various kinds of non carbonated beverages. The Group sells these beverages, concentrates and syrups to bottling and canning operations, distributors, fountain wholesalers and retailers. The other products marketed and distributed by the Group include juice drinks, sports drinks, water products, teas, coffees and other beverage products. The Group also has ownership interests in various canning and bottling operations. The operations of the Group are conducted in the United States, Europe, Eurasia, Middle East, Africa, Latin America and Asia.

Coca-Cola Co

Coca-Colas stronger-than-expected second-quarter results and raised full-year outlook have fueled a rally and fresh highs, with traders citing resilient demand and volume growth. Many welcome KO as a defensive holding and momentum leader, while others question its elevated valuation and warn the run may be stretched.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is drawing attention for a rebound and breakout attempt, with traders speculating that its high short interest could amplify the move through short covering. Bullish discussion points to stronger bookings and positive cash flow, while skeptics emphasize declining revenue, continued losses, and a cautious outlook.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastems planned VS-7375 clinical update across pancreatic, lung and colorectal cancers is the main focus, with traders weighing encouraging GenFleet results against the need for Verastems own data to establish efficacy, durability and tolerability. Community optimism has been reinforced by debate over competing KRAS drug data, though some remain cautious about whether VS-7375 can differentiate itself.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta Personals launch, including ACH banking features and reported Visa Direct and Bivo Cash integrations, has put KTA in focus as traders debate its potential as fiat-payment infrastructure. Bulls see the rollout as a step toward real-world adoption, while skeptics argue that sustained network activity and usagenot announcements aloneare needed to support the price.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

XCNs gain has sparked breakout and accumulation talk, with bullish traders pointing to Onyxs broader buildoutincluding Chains payments technology and neobank plansas a longer-term rationale. Others doubt the move will hold, citing thin volume, selling pressure, and a history of fading rallies.

PG&E Corp. operates as a holding company, which engages in generation, transmission, and distribution of electricity and natural gas to customers. It specializes in energy, utility, power, gas, electricity, solar, and sustainability. The company was founded on November 17, 1995 and is headquartered in Oakland, CA.

PG&E Corp.

Uncertainty over California wildfire-liability reform is driving attention: the legislation failed to advance in the form utilities wanted, contributing to a selloff and analyst downgrades, while reports that the measure was halted prompted hopes of a rebound. Traders are divided between viewing the decline as an overreaction and fearing unresolved wildfire exposure and further downside.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

Traders are focused on claims of a BONK security breach and its delisting from Upbit, which they link to selling pressure; the details and impact are debated. Some see the weakness as a buying opportunity, while others warn of further losses, alongside speculation about a Bonk.fun relaunch and renewed meme-coin momentum.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna is drawing attention after positive registrational-trial results for miv-cel in stiff person syndrome and encouraging longer-term myasthenia gravis data, strengthening discussion of its FDA filing path. Traders are bullish on the therapys potential but debate the sharp, volatile reaction, including concerns about serious adverse events, profit-taking and possible dilution.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

BW is drawing attention after a sharp selloff despite reported earnings strength and optimism about its AI data-center power business. Traders are divided over whether the companys large, concentrated Applied Digital/Base Electron project can overcome permitting uncertainty and support further growth, while others see the decline as excessive.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

FDA review documents highlighting a weaker daraxonrasib response rate in the KRAS G12D pancreatic-cancer subgroup have unsettled investors and intensified comparisons with Verastems competing G12D program. Traders debate whether the subgroup response data outweigh broader survival results, with some viewing the selloff as an overreaction and others questioning the drugs efficacy in that mutation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside

Equity

Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.


Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday

The text discusses recent gains in the stock market, particularly for companies like Napco Security Technologies and SuperX AI Technology. US stocks were mixed, with the Dow Jones index gaining 150 points. Napco Security Technologies rose after better-than-expected results. Other big gainers...

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -83.33% and +6.72%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -3.90% and +6.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of +31.96% and +3.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings; other stocks declining in pre-market tradingread more...

Alvotech (ALVO) Receives FDA Form 483 Following Routine Facility Inspection

Alvotech (ALVO) Receives FDA Form 483 Following Routine Facility Inspection...

ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs 

Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$5.78
Prev Close	$5.67
Open	$5.67
Dividend Yield	0.00%
50-Day Moving Average	$5.00
Beta	0.71
Avg. Volume	1.16M
PE Ratio	-10.37

52-Week High	$9.05
52-Week Low	$2.94
Market Capitalization	$2.26B
EPS (Annual)	$0.0964
Price to Book	-10.77
Revenue Per Employee	$401,589.73

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALVO Fundamentals